Neuropathy & Nerve Health: A Nutritional and Natural-Health Reference
1. Definition and Overview
Peripheral neuropathy refers to the many conditions that involve damage to the peripheral nervous system, the vast communication network that sends signals between the central nervous system (the brain and spinal cord) and all other parts of the body. Peripheral neuropathies encompass disorders of peripheral nerve cells and fibers, manifesting secondary to a wide range of pathologies β including cranial nerves, spinal nerve roots and ganglia, nerve trunks and divisions, and autonomic nervous system nerves.
Peripheral nerves send many types of sensory information to the central nervous system (CNS), such as a message that the feet are cold. They also carry signals from the CNS to the rest of the body β including signals to the muscles that tell them to contract, as well as signals that help control the heart and blood vessels, digestion, and urination. When peripheral nerves can't send and receive signals like they should, it can have serious consequences for the body.
More than 20 million people in the United States have been estimated to have some form of peripheral neuropathy, but this figure may be significantly higher β not all people with symptoms of neuropathy are tested for the disease, and tests currently don't look for all forms of neuropathy. About 2.4% of the world population is affected by peripheral nerve disorders; the prevalence increases to 8% in older populations.
2. Classification of Peripheral Neuropathies
More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Specific impaired function and symptoms depend on the type of nerves β motor, sensory, or autonomic β that are damaged.
Peripheral neuropathy may be classified according to the number and distribution of nerves affected (mononeuropathy, mononeuritis multiplex, or polyneuropathy), the type of nerve fiber predominantly affected (motor, sensory, autonomic), or the process affecting the nerves β such as inflammation (neuritis), compression (compression neuropathy), or chemotherapy-induced peripheral neuropathy.
Several methods classify peripheral neuropathies, including mononeuropathies, multifocal neuropathies, and polyneuropathies. Further subclassifications can be made by separating peripheral neuropathies as axonal, demyelinating, or mixed β a distinction essential for treatment and management.
- Mononeuropathy: Mononeuropathy is a type of neuropathy that only affects a single nerve. Diagnostically, it is important to distinguish it from polyneuropathy because when a single nerve is affected, it is more likely to be due to localized trauma or infection.
- Polyneuropathy: More often, many or most of the nerves are affected (called polyneuropathy).
- Length-dependent neuropathy: Most neuropathies are "length-dependent," meaning the farthest nerve endings from the brain (those in the feet) are where the symptoms develop first or are worst. In severe cases, these neuropathies can spread upward toward the central parts of the body.
3. Presentation and Symptoms
The most frequently encountered symptoms of peripheral neuropathy include numbness and paresthesias; pain, weakness, and loss of deep tendon reflexes may accompany these symptoms. Peripheral neuropathies usually develop over months to years, while some may develop more rapidly and be progressive. Peripheral neuropathies have a broad range of severity and clinical manifestations, as they can affect motor, sensory, and autonomic fibers.
Peripheral neuropathy occurs when peripheral nerves fail to carry information to and from the brain and spinal cord, resulting in pain, loss of sensation, or inability to control muscles. In some cases, the failure of nerves that control blood vessels, intestines, and other organs results in abnormal blood pressure, digestion problems, and loss of other basic body processes.
In distal symmetrical polyneuropathy, characteristic features include pain, numbness, a burning sensation, decreased vibration sense, and ankle tendon reflexes.
4. Body Systems Involved
Peripheral neuropathy involves multiple physiological systems beyond the nervous system itself:
- Peripheral nervous system: Sensory, motor, and autonomic nerve fibers are all potentially affected, depending on the type and cause of neuropathy.
- Cardiovascular system: Peripheral nerve signals help control the heart and blood vessels. Autonomic neuropathy can therefore affect heart rate and blood pressure regulation.
- Gastrointestinal system: Autonomic fiber damage can impair digestion and gut motility.
- Musculoskeletal system: Motor nerve damage leads to muscle weakness and wasting in affected regions.
- Metabolic system: The pathogenesis of diabetic neuropathy involves a complex process including hyperglycemia-induced oxidative stress and altered polyol metabolism that changes the nerve microvasculature, altered growth factor support, and deregulated lipid metabolism.
5. Contributing and Associated Factors
5.1 Diabetes and Metabolic Syndrome
Diabetic neuropathy occurs in approximately half of individuals with chronic type 1 and type 2 diabetes. In addition to hyperglycaemia, dyslipidaemia is increasingly viewed as a contributing pathogenic factor to neuropathy, particularly for type 2 diabetes. This direction stems from a 2012 Cochrane review that indicated that intense glycaemic control only marginally improved neuropathy in multiple type 2 diabetes cohorts. Rather, metabolic syndrome components, such as obesity, emerged as key players in neuropathy risk.
In diabetes, excess glucose and lipids lead to oxidative stress, which damages mitochondria and disrupts normal cellular function. Several studies have reported that some patients with prediabetes develop neuropathic complications, whereas others demonstrated little evidence of neuropathy even after long-standing diabetes.
5.2 Nutritional Deficiencies
Testing for vitamin and mineral deficiencies such as copper, thiamine, pyridoxine, folate, B12, and vitamin E is clinically relevant because these nutrients play fundamental roles in nervous system development and maintenance.
Vitamin B12 deficiency can cause sensory neuropathy due to myelin production interference β myelin being the fatty substance that surrounds and insulates nerves. Cobalamin plays an important role in the intracellular methylation process of homocysteine to methionine (a folate-dependent cycle). Therefore, any deficiency in cobalamin results in hyperhomocysteinemia, which has shown toxic effects on neuronal cells (especially for myelin sheaths) and vascular endothelium.
5.3 Alcohol Use
Alcohol abuse is known to cause a range of neurological disorders, including cerebellar ataxia, confusion, cognitive impairment, and peripheral neuropathy. Chronic heavy alcohol consumption is associated with both direct toxic effects on nerve tissue and secondary nutritional deficiencies, particularly thiamine.
5.4 Toxic and Pharmacological Causes
Several drug classes of chemotherapy cause neuropathy with high incidence in a dose-dependent fashion. There has been extensive research in chemotherapy-induced peripheral neuropathy (CIPN) in order to prevent this dreaded complication that results in dose reductions of medications used to treat cancers.
Since more than 40 years ago, there has been evidence linking metformin to a deficiency of vitamin B12. Several interventional investigations, observational studies, and meta-analyses have supported this association. Metformin-treated type 2 diabetes mellitus patients are at higher risk of vitamin B12 deficiency and more severe neuropathy symptoms.
5.5 Infection
A recent systematic review reported that 31% of patients with HIV develop peripheral neuropathy. Globally, leprosy remains a common cause of peripheral neuropathy, with the highest prevalence in Southeast Asia.
5.6 Genetic and Idiopathic Causes
Most instances of neuropathy are either acquired β meaning the neuropathy is not present from the beginning of life β or genetic. Acquired neuropathies are either symptomatic (the result of another disorder or condition) or idiopathic (meaning it has no known cause). The most common genetic sensorimotor polyneuropathy is Charcot-Marie-Tooth disease, specifically type 1a.
5.7 Renal and Uremic Neuropathy
Uremic polyneuropathy is characterized by demyelination and axonal degeneration. The cause is not entirely clear, but it may be related to thiamine, zinc, biotin deficiencies, and decreased transketolase activity. Other contributing factors include increases in phenols, myoinositol, beta2-microglobulin, hyperparathyroidism, and hyperkalemia.
6. Nutrients, Herbs, and Natural Ingredients
6.1 B Vitamins
Vitamin B12 (Cobalamin)
Traditional Use: Vitamin B12 deficiency has been recognized as a cause of neurological disease for over a century, particularly in the context of pernicious anemia and subacute combined degeneration of the spinal cord. Clinicians in the early and mid 20th century documented peripheral nervous system involvement in patients with deficiency states.
Scientific Evidence: Peripheral neuropathy is common in patients with diseases associated with deficiency of the B-vitamins, and vitamin treatment has shown mixed results. A systematic review and meta-analysis studied the association between PN/pain and B-vitamin biomarkers and the effect of vitamin treatment. PubMed and Web of Science were searched; a total of 46 observational and seven interventional studies were identified.
The presence of peripheral neuropathy was associated with lowered B12 levels (pooled estimate 1.51 [95% CIs 1.23β1.84], n = 34, Cochran Q Test IΒ² = 43.3%, p = 0.003) and elevated methylmalonic acid and homocysteine.
Supplementation improved neurological symptoms in patients with overt deficiency, with oral therapy showing similar efficacy to intramuscular injections, better tolerability, and lower cost. In older adults with subclinical deficiency, supplementation did not significantly improve cognitive or neurological outcomes. In diabetic patients with neuropathy, improvements were noted in symptom scores, but not in objective neurological measures. Although reductions in homocysteine levels were observed, these biochemical changes did not consistently correlate with clinical improvements.
The evidence is strongest when supplementation is given to individuals with overt, documented B12 deficiency. Vitamin B12 supplementation is effective for patients with clinical deficiency but shows limited neurological benefit in subclinical cases; further trials using standardized outcomes and longer follow-up are needed. Evidence strength: moderate to strong for deficiency correction; weak to moderate for supplementation in non-deficient individuals.
Vitamin B1 (Thiamine) and Benfotiamine
Traditional Use: Thiamine deficiency has been linked to neurological disease in medical history at least since the description of beriberi β a disorder with significant peripheral neuropathy β documented particularly in populations consuming polished white rice. The association was established in the early 20th century.
Scientific Evidence: Benfotiamine has been shown to be more effective than thiamine in preventing diabetic complications, such as neuropathy and nephropathy. This is due, in part, to benfotiamine's ability to increase intracellular levels of thiamine pyrophosphate, a coenzyme involved in glucose metabolism.
There is presently sparse data to support a particular management strategy in alcohol-related peripheral neuropathy, but the limited data available appears to support the use of vitamin supplementation, particularly of B-vitamin regimens inclusive of thiamine. For alcoholic neuropathy specifically, where thiamine deficiency is often a direct contributor to the nerve damage, the case for thiamine supplementation is strong, and benfotiamine's superior bioavailability makes it the logical choice over standard thiamine.
Results of clinical trials in diabetic neuropathy are mixed. Despite a marked improvement in thiamine status, long-term high-dose benfotiamine (300 mg/day over 24 months) had no significant effect on peripheral nerve function or inflammatory markers in patients with type 1 diabetes. A separate 12-month trial in type 2 diabetes found that the changes from baseline to 12 months in corneal nerve fiber length did not differ between benfotiamine and placebo groups. The corresponding changes in secondary morphometric, functional, and clinical neuropathic outcomes were also similar in the two groups, and only the Neuropathy Symptom Score tended to improve after benfotiamine treatment (p=0.098 vs placebo).
Evidence strength: Strong for thiamine deficiency states (alcoholic neuropathy, beriberi); mixed and currently insufficient for diabetic neuropathy in non-deficient individuals.
Vitamin B6 (Pyridoxine)
Traditional and Clinical Context: Therapeutic doses of the B-vitamins (B1, B6, and/or B12) are commonly used in patients with peripheral neuropathy, but there are no evidence-based guidelines as to whether vitamin deficiency should be suspected or treated in such patients. Notably, high-dose B6 supplementation (typically above 200β500 mg/day over prolonged periods) is itself a recognized cause of sensory neuropathy, documented in the clinical literature. The optimal and safe dose range for B6 in neuropathy contexts requires careful consideration.
Evidence strength: Weak to uncertain for benefit; excess B6 is a recognized neurotoxic risk. Deficiency correction may be relevant in specific populations.
6.2 Alpha-Lipoic Acid (ALA)
Traditional Use: Alpha-lipoic acid is not a traditional herbal remedy but rather an endogenous antioxidant compound discovered in the mid-20th century. It began to be used medically in Germany for diabetic neuropathy starting in the 1990s and has been approved for this indication in some European countries.
Scientific Evidence: ALA is the most extensively studied natural compound in the context of peripheral neuropathy. Alpha-lipoic acid was found to improve the symptoms in patients with diabetic sensorimotor peripheral neuropathy (DSPN) by reducing oxidative stress and ameliorating microcirculation.
A meta-analysis of randomized controlled trials found: The pooled standardized mean difference estimated from all trials revealed a reduction in TSS (Total Symptom Score) scores of β2.26 (CI: β3.12 to β1.41; P = 0.00001) in favour of alpha-lipoic acid administration.
A systematic review of intravenous ALA found: Compared with the control group, nerve conduction velocities increased significantly in the treatment group. The meta-analysis provides evidence that treatment with ALA (300β600 mg/day i.v. for 2β4 weeks) is safe and that the treatment can significantly improve both nerve conduction velocity and positive neuropathic symptoms. However, the evidence may not be strong because most of the studies included have poor methodological quality.
Evidence strength: Moderate for symptomatic relief of diabetic neuropathy (multiple RCTs and meta-analyses); limitations include methodological heterogeneity across trials. Intravenous administration has the most consistent data. Evidence for non-diabetic neuropathies is more limited.
6.3 Acetyl-L-Carnitine (ALC)
Traditional Use: L-carnitine is an endogenous molecule involved in fatty acid metabolism. Acetyl-L-carnitine is not a traditional herbal compound; its investigation for neuropathy began in the latter decades of the 20th century based on observed roles in nerve metabolism and regeneration.
Scientific Evidence: Acetyl-L-carnitine is an ester of L-carnitine, both endogenous molecules, with a vital role in lipid metabolism. Exogenously delivered acetyl-L-carnitine is endowed with neuroprotective and neurotrophic actions due to its antioxidant and metabolic properties. Moreover, it is an epigenetic regulator of genes involved in analgesia and of neurotrophic factors including nerve growth factor. Its long-term neurotrophic and analgesic activity has been confirmed in animal models of chronic inflammatory and neuropathic pain and in clinical studies.
A systematic review and meta-analysis including four RCTs (n = 523) found: Compared with placebo, ALC significantly reduced VAS scores of peripheral neuropathic pain patients. The review concluded: the current evidence suggests that ALC has a moderate effect in reducing pain measured on VAS in peripheral neuropathic pain patients with acceptable safety. Larger trials with longer follow-up, however, are warranted to establish the effects.
Evidence strength: Preliminary to moderate; most positive data come from diabetic neuropathy populations. The evidence base is smaller than for ALA and intravenous alpha-lipoic acid. Larger, better-designed RCTs are needed.
6.4 Omega-3 Fatty Acids (EPA and DHA)
Traditional Use: Consumption of marine foods rich in omega-3 fatty acids has been a dietary staple in many coastal and Arctic populations for centuries. Their anti-inflammatory properties in the context of nerve health are an area of 20th- and 21st-century scientific investigation.
Scientific Evidence: Fish oil is an excellent source for the nutrition-dependent omega-3 PUFAs, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These fatty acids are the source of anti-inflammatory metabolites known as resolvin, neuroprotectin, and maresin. Preclinical studies have demonstrated that the metabolites of EPA and DHA are neuroprotective.
Inflammation is a characteristic of damaged nerves, and the anti-inflammatory effects of the omega-3 fatty acids in fish oil are well known. Preclinical (animal) research has shown that multiple sources of omega-3 PUFA are capable of serving as treatment for obesity- and pre-diabetes-related peripheral neuropathy and vascular dysfunction of epineurial arterioles.
Human clinical evidence is more limited. Reviews of multiple studies conclude that omega-3 supplementation can offer modest but meaningful relief of neuropathic pain and may improve nerve function tests. Experts note that benefits tend to be dose-dependent and may take several months. However, there is a need for larger, better-controlled clinical trials to investigate the effect of omega-3 fatty acids on peripheral nerve integrity.
Evidence strength: Preclinical data (animal models) are reasonably consistent; human clinical evidence is preliminary and requires larger RCTs. The anti-inflammatory mechanism is biologically plausible.
6.5 Magnesium
Traditional and Nutritional Context: Magnesium is an essential mineral involved in hundreds of enzymatic reactions. Its role in neuromuscular function has long been recognized in clinical medicine.
Scientific Evidence: Magnesium is critical in glucose metabolism and maintaining healthy insulin sensitivity. Low magnesium is correlated with oxidative stress. While results are mixed, research indicates a possible association between magnesium and healthy peripheral nerve function.
A 2018 study involving people undergoing chemotherapy found that those who had high levels of magnesium in their diet were less likely to experience chemotherapy-related neuropathy; however, more studies are needed. A 2023 analysis found that both excessive and insufficient intake of magnesium and calcium may increase the likelihood of developing peripheral neuropathy.
A 2021 review concluded that magnesium may promote peripheral nerve regeneration; however, further research is necessary.
Evidence strength: Preliminary; mixed results in human studies. The association between deficiency and neuropathy risk is biologically plausible, but intervention trial data are sparse. An excess of magnesium carries its own risks.
6.6 Vitamin D
Traditional and Nutritional Context: Vitamin D's role in neurological function extends beyond its classical association with calcium metabolism and bone health. Receptors for vitamin D are found throughout the nervous system, and deficiency is common in many global populations.
Scientific Evidence: Studies link low vitamin D levels to increased nerve pain and worse diabetic neuropathy symptoms. Supplementation in deficient individuals can improve pain scores and nerve conduction measures.
Evidence strength: Preliminary to moderate for individuals with documented deficiency. Overall evidence base is limited by small sample sizes and methodological heterogeneity. The strongest signal is in deficient populations.
6.7 Curcumin (Turmeric)
Traditional Use: Curcuma longa (turmeric) has been used for centuries in Ayurvedic and traditional Chinese medicine as an anti-inflammatory agent for a broad range of conditions, typically as a dietary spice or prepared as a decoction. Its use in nerve-specific conditions is not historically documented as a primary indication in classical texts, but its anti-inflammatory application overlaps with inflammatory aspects of nerve damage.
Scientific Evidence: The evidence for curcumin on peripheral nerves is sparse, with a 2013 study on rats providing the crux of the evidence for its potential to support nerve health. Human clinical trial data in neuropathy specifically are very limited. The compound's poor bioavailability when taken orally has been a limiting factor in research, and formulations with enhanced bioavailability (e.g., complexed with phospholipids or piperine) are under investigation.
Evidence strength: Preclinical (animal/in vitro) only for neuropathy-specific claims. Human evidence is insufficient to draw conclusions. The anti-inflammatory mechanism is biologically plausible but not yet confirmed in clinical trials for nerve health.
6.8 Zinc
Traditional and Nutritional Context: Zinc is an essential trace mineral with roles in immune function, protein synthesis, and neurological signaling. Nutritional reviews exploring the role of zinc in neuropathic pain have examined its proposed mechanisms of action, efficacy, and evidence supporting its use. Zinc deficiency can impair neurological function and has been noted in uremic neuropathy contexts.
Evidence strength: Very preliminary; human trial data specifically for neuropathy are limited. Correction of documented zinc deficiency may be relevant in specific populations.
7. Dietary and Lifestyle Factors
7.1 Overall Dietary Patterns
Plant-based, Mediterranean, and Nordic diets rich in whole grains, vegetables, legumes, nuts, seeds, fiber, and olive oil influence the pathogenesis of autoimmune, inflammatory, and metabolic conditions by conferring additional neuroprotective and anti-inflammatory effects, such as reducing oxidative stress and modulating neuroinflammation.
A systematic review of dietary lifestyle interventions for neuropathic pain reported: The dietary lifestyle interventions studied included low-fat plant-based, plant-based fasting-mimicking, low-calorie, potassium-reduced, gluten-free, and intermittent high-protein/Mediterranean diets. The included studies described some statistically significant improvements in pain severity on objective quantitative sensory testing, electrophysiology, imaging, and subjective questionnaires. No serious adverse events were identified, and dietary interventions were generally well tolerated. The data indicate that dietary lifestyle interventions may offer a low-risk, low-cost option for chronic neuropathic pain management, potentially improving quality of life and reducing overall morbidity.
Several studies have shown that diets promoting adequate vitamin and mineral intake enhance the analgesic effect of standard therapies, thereby alleviating symptoms associated with the inflammatory demyelinating processes underlying neuropathic pain.
7.2 Glycemic Control and Obesity
Metabolic syndrome components, such as obesity, emerged as key players in neuropathy risk. Diets seeking to improve physiological health, support gut barrier integrity, and decrease systemic inflammation have been effective in managing metabolic syndromes, ultimately reducing the overall morbidity of diabetic neuropathy. For type 1 diabetes, tighter glycaemic control has a more robust effect on neuropathy prevention than in type 2 diabetes, where metabolic complexity plays a greater role.
7.3 Alcohol Reduction
Chronic heavy alcohol use is a well-documented risk factor for peripheral neuropathy through both direct nerve toxicity and secondary nutritional depletion. The limited data available appear to support the use of B-vitamin supplementation, particularly thiamine-inclusive regimens, in managing alcohol-related peripheral neuropathy. Reduction or cessation of alcohol consumption is emphasized in the literature as foundational for individuals with alcohol-related nerve damage.
7.4 Exercise and Physical Activity
Physical exercise is one of the most consistently studied non-pharmacological lifestyle interventions for neuropathy. A systematic review and meta-analysis concluded: Exercise interventions, including aerobic, resistance, and balance training, show beneficial effects on neuropathic symptoms, nerve conduction, glycemic control, and postural stability in patients with diabetic peripheral neuropathy. Combined aerobic and resistance training appears more effective than single-mode interventions in reducing HbA1c and improving metabolic outcomes.
For diabetic peripheral neuropathy, evidence-based recommendations can now be made, suggesting a combination of endurance and sensorimotor training to be most beneficial. For patients with chemotherapy-induced peripheral neuropathy, sensorimotor training remains the most crucial component. For all other neuropathies, more high-quality research is needed. Overall, sensorimotor training has great potential to target most neuropathies and, combined with endurance training, is currently considered the best exercise option for neuropathies.
A separate meta-analysis found that exercise significantly improved key musculoskeletal outcomes: Exercise significantly increased ankle dorsiflexion range of motion, hallux strength, toe strength, and lower extremity functional strength, while reducing glycosylated hemoglobin and body mass index in patients with diabetic peripheral neuropathy.
There is convincing evidence that aerobic exercise not only reverses established neuropathic pain but also prevents its development. Aerobic exercise seems more beneficial than resistance exercise for motor nerve regeneration and functional recovery, although this remains to be confirmed.
7.5 Deficiency Screening
Although there are no standard laboratory or imaging studies to test for peripheral neuropathies, certain studies may aid in the diagnosis and help narrow down the underlying cause β including testing for macrocytic anemia (which may indicate vitamin B12 or folate deficiency or alcohol abuse) and metabolic panels to look for electrolyte imbalances and renal failure, as uremia can also lead to neuropathy. Targeted correction of documented nutritional deficiencies is generally recognized as more evidence-based than broad supplementation in non-deficient individuals.
References
Go back